B-2065

N/A

Report date: 2026/01/29 20:00:06

Base Information

Drug NameB-2065
Drug Alias NameB-2065
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokeStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Tasly Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsIschemic StrokeStroke
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A